RESEARCH



The significance of admission blood lactate and fibrinogen in pediatric traumatic brain injury: a single-center clinical study

Kun-yuan Zhang¹ · Pei-long Li² · Peng Yan³ · Cheng-jian Qin³ · Hao He¹ · Chang-pin Liao⁴

Received: 13 September 2023 / Accepted: 15 December 2023 / Published online: 26 December 2023 © The Author(s) 2023

Abstract

Background Traumatic brain injury (TBI) is a significant cause of morbidity and mortality in pediatric patients, leading to long-term physical, cognitive, and psychological impairments. Blood lactate and fibrinogen levels have emerged as potential biomarkers associated with tissue hypoperfusion and coagulation dysfunction, respectively. However, limited research has specifically focused on the significance of these biomarkers in pediatric TBI. This study aimed to investigate the clinical significance of blood lactate and fibrinogen levels upon admission in pediatric patients with traumatic brain injury.

Methods The medical records of 80 children with a traumatic brain injury who were admitted from January 2017 to January 2021 were retrospectively analyzed. The two groups were compared according to whether the blood lactate in the admission arterial blood gas increased and the fibrinogen content in the coagulation function decreased. The clinical data of the children in the two groups were different, and then they were divided into a good prognosis group and a poor prognosis group according to the GOS prognostic score, and the differences in the clinical indicators of the two groups were compared.

Results Among the 80 patients, 33 had elevated blood lactate levels, 34 had decreased fibrinogen levels, and 29 had an unfavorable outcome (GOS < 4). Compared to the normal blood lactate group, there were no statistically significant differences in age, sex ratio, or platelet count in the elevated blood lactate group (P > 0.05). However, the elevated blood lactate group had lower Glasgow Coma Scale (GCS) scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stay, lower GOS scores, and a higher proportion of GOS < 4 (P < 0.05). Compared to the normal fibrinogen group, there were no statistically significant differences in age, sex ratio, or platelet count in the decreased fibrinogen group (P > 0.05). However, the decreased fibrinogen group had lower GCS scores upon admission, higher blood lactate levels, longer hospital stays, lower GOS scores, and a higher proportion of GOS < 4 (P < 0.05). Compared to the favorable outcome group, there were no statistically significant differences in age, sex ratio, or platelet count in the unfavorable outcome group, there were no statistically significant differences in age, sex ratio, or platelet count in the unfavorable outcome group, there were no statistically significant differences in age, sex ratio, or platelet count in the unfavorable outcome group, there were no statistically significant differences in age, sex ratio, or platelet count in the unfavorable outcome group (P > 0.05). However, the unfavorable outcome group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, a higher incidence of pulmonary infection, a higher incidence of stress ulcers, and lower GOS scores (P < 0.05).

Conclusion The levels of blood lactate and fibrinogen may represent the severity of children with traumatic brain injury and may be risk factors for poor prognosis of children with traumatic brain injury.

Keywords Blood lactate · Fibrinogen · Traumatic brain injury · Children

Kun-yuan Zhang and Pei-long Li contributed equally to this work.

Chang-pin Liao qinchengjian47@163.com

- ¹ Department of Neurosurgery, Second People's Hospital of Pingchang, Pingchang, Sichuan, P.R. China
- ² Kunming Children's Hospital, Children's Hospital Affiliated to Kunming Medical University, Kunming Medical University, Kunming, P.R. China
- ³ Department of Neurosurgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, P.R. China
- ⁴ Department of Neurosurgery, People's Hospital of Baise, No. 8, Chengxiang Street, Youjiang District, Baise, Guangxi, P.R. China

Introduction

Trauma is reported as the leading cause of mortality among children in developed countries, with TBI accounting for a significant proportion of these fatal traumatic conditions [1]. Children, due to their ongoing organ system development, undergo complex and varied pathological and physiological changes following TBI, which may lead to various complications and long-term sequelae. These can include psychiatric and cognitive abnormalities, seizures, speech and motor function impairments, and in some cases, these complications can have lifelong implications, imposing significant pressure on the affected children, their families, and society [2, 3].

Materials and methods

Clinical data

We collected medical records of 80 pediatric patients with TBI who were admitted to the Department of Neurosurgery from January 2017 to January 2021. The inclusion criteria were as follows [3–6]: (1) Age \leq 18 years with a documented history of trauma; (2) Confirmed diagnosis of TBI based on head CT scan; and (3) Hospital admission within 24 h of injury. The exclusion criteria were as follows: (1) Age > 18 years or unclear history of trauma; (2) Admission to the hospital more than 24 h after the injury; and (3) The presence of multiple injuries, complex injuries, or concomitant significant organ system diseases involving the heart, liver, lungs, kidneys, etc.

Methods

Data collection

Clinical data of the pediatric patients were collected by retrieving records from the hospital's medical record system. The following information was recorded: baseline characteristics upon admission, including demographic indicators, time of injury, mechanism of injury, duration from injury to hospital admission, and GCS score upon admission; relevant examination results, including blood lactate level, coagulation function, platelet count, and CT scan findings; and the progression of the patients' condition and outcome indicators, including surgical treatment, intracranial infection, pulmonary infection, stress ulcers, and GOS score at 3 months (GOS \geq 4 indicated a favorable prognosis).

Specimen collection methods and criteria

Arterial and venous blood samples were collected within 30 min after admission. Arterial blood samples were used for arterial blood gas analysis, while venous blood samples were used for fibrinogen detection. Blood lactate levels were measured using the arterial blood lactate obtained from arterial blood gas analysis. The measurements were performed using a blood gas analyzer and corresponding reagent kit produced by Shenzhen Mindray Bio-Medical Electronics Co., Ltd., using dry chemistry or the alternating current impedance method for analysis. Fibrinogen levels were determined using the ACL TOP700 fully automated coagulation analyzer and fibrinogen assay kit (clotting method) for venous blood fibrinogen measurement. A blood lactate level greater than 2.2 mmol/L was considered elevated, while a blood lactate level of 2.2 mmol/L or lower was considered normal. A fibrinogen level less than 2.0 g/L was considered decreased, while a fibrinogen level between 2.0 g/L and 4.0 g/L was considered normal.

Statistical analysis

The clinical data and analyzed data were recorded using Microsoft 2016 and analyzed using SPSS 23.0. Normally distributed continuous data are presented as the mean \pm standard deviation ($X \pm S$), and the comparison of the means between two groups were performed using a t test. Nonnormally distributed data were presented as the median and interquartile range (M [P25, P75]). Categorical data are presented as the relative numbers or rates, and the chi-square test was used for comparison.

Results

Comparison of the clinical data between the elevated blood lactate group and normal blood lactate group

Among the 80 patients, 33 had elevated blood lactate levels. There were no significant differences between the elevated blood lactate group and the normal blood lactate group in terms of age, sex ratio, and platelet count (P > 0.05, Table 1). However, the elevated blood lactate group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, lower GOS scores, and a higher proportion of patients with GOS < 4 (P < 0.05, Table 1).

elevated blood lactate group and the normal blood lactate group age (years) 8.55 ± 1.70 8.79 ± 1.74 0.617 0.54 age (years) 8.55 ± 1.70 8.79 ± 1.74 0.617 0.54 blood lactate group platelet count 197.79 ± 54.63 199.28 ± 55.59 0.119 0.91 fibrinogen level 1.77 ± 0.67 2.32 ± 0.63 3.763 $<0.001^*$ GCS score at admission 6.61 ± 1.46 12.34 ± 2.00 14.035 $<0.001^*$ Core score at admission 6.525 ± 4.4 4.92 ± 0.66 9.58 $<0.001^*$ good prognosis 257 4 4.92 ± 0.66 9.58 $<0.001^*$ good prognosis 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 ge (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (male/female) 20.14 2.719 0.000 0.990 groupgender (male/female) 20.14 2.719 0.000 0.990 gender (male/female) 20.14 2.719 0.000 0.990 groupfibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001^*$ for locate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001^*$ good prognosis 7.34 ± 2.36 11.89 ± 2.62 7.934 $<0.001^*$ good prognosis 1.49 ± 0.40 16.39 ± 9.42 5.732 $<0.001^*$ good prognosis 24 5 30.170 $<0.001^*$ good prognosis 24 5 <t< th=""><th rowspan="10"></th><th>clinical data</th><th>elevated blood lactate group(n=33)</th><th>normal blood lactate group(n=47)</th><th>t/c2</th><th>P value</th></t<>		clinical data	elevated blood lactate group(n=33)	normal blood lactate group(n=47)	t/c2	P value
gender (male/temale)201327/200.0800.78blood lactate level2.55 ± 0.311.66 ± 0.331.2.200<0.001*		age (years)	8.55 ± 1.70	8.79 ± 1.74	0.617	0.54
		gender (male/female)	20/13	27/20	0.080	0.78
Note: * indicates statistically groupfibrinogen level 1.77 ± 0.67 2.32 ± 0.63 3.763 $<0.001^{*}$ Note: * indicates statistically significant differences ($P < 0.05$) 6.61 ± 1.46 12.34 ± 2.00 14.025 $<0.001^{*}$ Table 2 Comparison of clini- cal characteristics between the decreased fibrinogen group 2.94 ± 0.788 4.49 ± 0.66 9.58 $<0.001^{*}$ Table 2 Comparison of clini- cal characteristics between the 		blood lactate level	2.55 ± 0.31	1.66 ± 0.33	12.200	< 0.001*
Note: * indicates statistically significant differences ($P < 0.05$)GCS score at admission 2.873 ± 8.89 6.61 ± 1.46 12.34 ± 2.00 14.035 5.998 $<0.001^*$ $<0.001^*$ Table 2 Comparison of clinical characteristics between the orgony and the normal fibrinogen level groupclinical datadecreased fibrinogen level group(n=34) $\nu/c2$ P valueclinical datadecreased fibrinogen level group(n=34)age (years) age (years) 8.53 ± 1.83 8.63 ± 1.64 0.000 0.990 fibrinogen level fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001^*$ Note: * indicates statistically significant differences ($P < 0.05$) C^2 P value $Colspan="4">Colspan="4">C^2P valueColspan="4">Colspan="4">C^2P valueColspan="4">Colspan="4">COls$		platelet count	197.79 ± 54.63	199.28±55.59	0.119	0.91
Note: * indicates statistically significant differences ($P < 0.05$)Length of stay GOS score $2.8, 73 \pm 8.89$ 16.36 ± 9.20 5.998 $<0.001^*$ good $prognosis$ Table 2 Comparison of clinical characteristics between the decreased fibrinogen level group and the normal fibrinogen level group group $1/c2$ P valueClinical datadecreased fibrinogen level group($n=34$) $1/c2$ P valueClinical datadecreased fibrinogen level group($n=34$) $1/c2$ P valueage (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (male/female) ibrinogen level $20/14$ $27/19$ 0.000 0.990 gibrinogen levelAd 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001^*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission GCS score 3.03 ± 0.80 4.46 ± 0.75 8.183 0.001^* colspan="4">colspan="4">colspan="4">colspan="4">Clinical datapoor prognosis 24 5 30.170 $<0.001^*$ gender (male/female) $1/c13$ $31/20$ 0.240 0.624 poor prognosis $n=29$ good prognosis $(n=51)$ $t/c2$ P valueclinical datapoor prognosis $(n=29)$ good prognosis $(n=51)$ $t/c2$ P valueclinical datapoor prognosis $(n$		fibrinogen level	1.77 ± 0.67	2.32 ± 0.63	3.763	< 0.001*
Note: * indicates statistically significant differences (P < 0.05)GOS score poor prognosis 2.94 ± 0.788 2.5 4.49 ± 0.66 4.3 9.58 37.938 $<0.001^*$ 0.001^* god prognosisTable 2 Comparison of clinical cal characteristics between the decreased fibrinogen level group and the normal fibrinogen level group multiprognosis group $1/c2$ P value P valueClinical datadecreased fibrinogen level group(n=34) $1/c2$ level group(n=46)Point of clinical decreased fibrinogen level gender (male/female) poor prognosis 0.53 ± 1.83 2.0144 8.80 ± 1.64 2.719 0.000 0.990 		GCS score at admission	6.61 ± 1.46	12.34 ± 2.00	14.035	< 0.001*
Note: * indicates statistically significant differences ($P < 0.05$) poor prognosis 25 4 37.938 <0.001* Table 2 Comparison of clinical characteristics between the decreased fibrinogen level group(n=34) normal fibrinogen level group(n=34) normal fibrinogen level group(n=46) $l/c2$ P value ge (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 group 20/14 27/19 0.000 0.990 fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 <0.001*		Length of stay	28.73 ± 8.89	16.36 ± 9.20	5.998	< 0.001*
Note: * indicates statistically significant differences ($P < 0.05$) good prognosis 8 43 Table 2 Comparison of clinical characteristics between the decreased fibrinogen level group(n=34) normal fibrinogen level group(n=34) normal fibrinogen level group(n=46) $V/c2$ P value age (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (male/female) $20/14$ $27/19$ 0.000 0.990 group fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001^*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001^*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score 3.03 ± 0.80 4.44 ± 0.75 8.183 $<0.001^*$ good prognosis 24 5 30.170 $<0.001^*$ good prognosis 10 41 20^{-1} 1492 0.140 prognosis group ge (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.644 good prognosis group ge (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 <td>GOS score</td> <td>2.94 ± 0.788</td> <td>4.49 ± 0.66</td> <td>9.58</td> <td>< 0.001*</td>		GOS score	2.94 ± 0.788	4.49 ± 0.66	9.58	< 0.001*
significant differences $(P < 0.05)$ good prognosis 8 43 Table 2 Comparison of clinical characteristics between the decreased fibrinogen level group(n=34) normal fibrinogen $(rac/2 - P)$ value decreased fibrinogen level group(n=34) adecreased fibrinogen level group(n=34) age (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (malc/female) 20/14 27/19 0.000 0.990 fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 <0.001*		poor prognosis		4	37.938	< 0.001*
cal characteristics between the decreased fibrinogen level group (n=34)level group (n=34)level group (n=46)age (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 groupgender (male/female) $20/14$ $27/19$ 0.000 0.990 fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001*$ good prognosis 24 5 30.170 $<0.001*$ good prognosis 10 41 $20/40$ 0.624 por prognosis 24 5 30.170 $<0.001*$ good prognosis group and the good prognosis group $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001*$ platelet Count 20.041 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001*$ platelet Count 20.041 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.1		good prognosis	8	43		
cal characteristics between the decreased fibrinogen level group and the normal fibrinogen level groupcal characteristics between the devel group(n=34)level group(n=34)age (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (male/female)age (years) 8.53 ± 1.83 8.80 ± 1.64 0.705 0.48 gender (male/female)groupgender (male/female) $20/14$ $27/19$ 0.000 0.990 fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001*$ good prognosis 24 5 30.170 $<0.001*$ good prognosis 10 41 $20.01*$ $20.001*$ good prognosis group and the good prognosis group and the good prognosis group 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ blood lactate level 2.52 ± 0.36 <						
and the normal fibrinogen level groupage (years) 8.35 ± 1.83 8.0 ± 1.64 0.705 0.48 gender (male/female) $20/14$ $27/19$ 0.000 0.990 fibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001*$ CoS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001*$ good prognosis 24 5 30.170 $<0.001*$ good prognosis 10 41 $20/14$ $20/14$ $20/14$ clinical datapoor prognosis (n=29)good prognosis (n=51) $t/c2$ P valuegender (male/female)prognosis group 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 gender (male/female) $16/13$ $31/20$ 0.240 0.624 prognosis group 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001*$ platelet Count $20.94\pm 3.93\pm 11.78\pm 2.55$ 9.147 $<0.001*$ platelet Count $20.94\pm 3.93\pm 11.78\pm 2.55$ 9.147 <0.00	cal characteristics between the decreased fibrinogen level group and the normal fibrinogen level group	clinical data			t/c2	P value
groupgender (male/female) $20/14$ $27/19$ 0.000 0.990 fbrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001^*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001^*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001^*$ Length of stay 28.32 ± 8.87 16.39 ± 9.44 5.732 $<0.001^*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001^*$ good prognosis 24 5 30.170 $<0.001^*$ good prognosis 10 41 14922 0.140 reg (years) 8.31 ± 1.67 8.90 ± 1.72 1.4922 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 prognosis group 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ pulmonary infection 16 6 17.472 $<0.001^*$ Note: * indicates statistically 8 2 9.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$		age (years)	8.53 ± 1.83	8.80 ± 1.64	0.705	0.48
Solutionfibrinogen level 1.49 ± 0.30 2.53 ± 0.56 9.868 $<0.001^*$ blood lactate level 2.42 ± 0.37 1.74 ± 0.47 6.892 $<0.001^*$ platelet Count 199.64 ± 50.46 197.93 ± 58.43 0.137 0.89 GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001^*$ Length of stay 28.32 ± 8.87 16.39 ± 9.44 5.732 $<0.001^*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001^*$ poor prognosis 24 5 30.170 $<0.001^*$ good prognosis 10 41 10^{-1} $=0.001^*$ clinical dataclinical dataclinical datapoor prognosis (n=29)good prognosis (n=51) $t/c2$ P valuege (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 ge (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female)fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 <td>gender (male/female)</td> <td>20/14</td> <td>27/19</td> <td>0.000</td> <td>0.990</td>		gender (male/female)	20/14	27/19	0.000	0.990
Note: * indicates statistically prognosis groupclinical data poor prognosis (n=29) good prognosis (n=29) good prognosis (n=51)t/c2 (P < 0.001*)P valueClinical data age (years) gender (male/female)notal 16/13 $31/20$ 0.240 0.624 Clinical data good prognosis (n=29) 		fibrinogen level	1.49 ± 0.30	2.53 ± 0.56	9.868	< 0.001*
GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001*$ Note: * indicates statistically significant differences ($P < 0.05$)GCS score at admission 7.38 ± 2.36 11.89 ± 2.62 7.934 $<0.001*$ Note: * indicates statisticallyTable 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis group and the good prognosis group $(11ical data poor prognosis (n=29) good prognosis (n=51) t/c2 P valueclinical data poor prognosis (n=29) good prognosis (n=51) t/c2 P valueage (years)8.31 \pm 1.678.90 \pm 1.721.4920.140gender (male/female)following a give prognosis group and the goodprognosis group0.001*0.001*GOS score at admission6.79 \pm 1.678.90 \pm 1.721.4920.1400.140gender (male/female)16/1331/200.2400.6240.6246.79 \pm 1.670.001*8.90 \pm 1.721.4920.1400.6246.682.33 \pm 0.604.5170.001*0.1400.6240.2140.680.33 \pm 0.604.4330.001*0.650.650.94660.001*0.140$		blood lactate level	2.42 ± 0.37	1.74 ± 0.47	6.892	< 0.001*
Note: * indicates statistically significant differences $(P < 0.05)$ Length of stay GOS score 28.32 ± 8.87 16.39 ± 9.44 5.732 $<0.001^*$ GOS score 3.03 ± 0.80 4.46 ± 0.75 8.183 $<0.001^*$ Table 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis group $clinical datapoor prognosis (n=29)good prognosis (n=51)t/c2P valueage (years)8.31 \pm 1.678.90 \pm 1.721.4920.140gender (male/female)16/1331/200.2400.624blood lactate level2.52 \pm 0.361.74 \pm 0.428.348<0.001^*blood lactate level2.52 \pm 0.361.74 \pm 0.428.348<0.001^*Length of stay29.93 \pm 8.6416.65 \pm 9.006.443<0.001^*Length of stay29.93 \pm 8.6416.65 \pm 9.006.443<0.001^*Length of stay29.93 \pm 8.6416.65 \pm 9.006.443<0.001^*Length of stay2$		platelet Count	199.64 ± 50.46	197.93 ± 58.43	0.137	0.89
Note: * indicates statistically significant differences ($P < 0.05$)GOS score poor prognosis 3.03 ± 0.80 24 4.46 ± 0.75 5 8.183 30.170 $<0.001^*$ $<0.001^*$ Table 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis groupclinical data age (years)poor prognosis (n=29) 8.31 ± 1.67 good prognosis (n=51) $t/c2$ P value P value $prognosis groupClinical dataage (years)8.31 \pm 1.678.90 \pm 1.721.4920.1400.2409.00 d prognosis group1.67 \pm 0.682.33 \pm 0.604.517<0.001^*4.5179.01 lactate level2.52 \pm 0.361.74 \pm 0.428.348<0.001^*91atelet Count20.041 \pm 53.41197.67 \pm 56.160.2140.8310.2149.02 GCS score at admission6.79 \pm 1.9311.78 \pm 2.559.147<0.001^*0.001^*Note: * indicates statistically8.0 \pm 0.001^*1.66 \pm 9.006.443<0.001^*$		GCS score at admission	7.38 ± 2.36	11.89 ± 2.62	7.934	< 0.001*
Note: * indicates statistically significant differences ($P < 0.05$)poor prognosis good prognosis24530.170<0.001*Table 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis groupclinical datapoor prognosis (n=29)good prognosis (n=51) $t/c2$ P valueage (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001*$ volumenary infection 16 6 17.472 $<0.001*$ Note: * indicates statistically 8 2 9.466 0.002		Length of stay	28.32 ± 8.87	16.39±9.44	5.732	< 0.001*
Note: * indicates statistically significant differences $(P < 0.05)$ Image of prognosis1041Table 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis group $clinical data$ poor prognosis $(n=29)$ good prognosis $(n=51)$ $t/c2$ P value $age (years)$ 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001*$ Note: * indicates statisticallystress ulcer 8 2 9.466 0.002		GOS score	3.03 ± 0.80	4.46 ± 0.75	8.183	< 0.001*
significant differences $(P < 0.05)$ good prognosis 10 41 Table 3 Comparison of clinical characteristics between the poor prognosis group and the good prognosis group and the good prognosis group dinical data poor prognosis $(n=29)$ good prognosis $(n=51)$ $t/c2$ P value age (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ Note: * indicates statistically stress ulcer 8 2 9.466 0.002		poor prognosis	24	5	30.170	< 0.001*
characteristics between the poor prognosis group and the good prognosis groupis poor prognosis (n=21)is poor prognosis (n=		good prognosis	10	41		
characteristics between the poor prognosis group and the good prognosis groupintend datapoor prognosis (n=21)is colspan="2" intend dataage (years) 8.31 ± 1.67 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ volte: * indicates statisticallystress ulcer 8 2 9.466 0.002						
prognosis group and the good prognosis groupage (years) 8.31 ± 1.07 8.90 ± 1.72 1.492 0.140 gender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ volte: * indicates statisticallystress ulcer 8 2 9.466 0.002	characteristics between the poor prognosis group and the good	clinical data	poor prognosis (n=29)	good prognosis $(n=51)$	t/c2	P value
prognosis groupgender (male/female) $16/13$ $31/20$ 0.240 0.624 fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ Note: * indicates statisticallystress ulcer 8 2 9.466 0.002		age (years)	8.31 ± 1.67	8.90 ± 1.72	1.492	0.140
fibrinogen level 1.67 ± 0.68 2.33 ± 0.60 4.517 $<0.001^*$ blood lactate level 2.52 ± 0.36 1.74 ± 0.42 8.348 $<0.001^*$ platelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ pulmonary infection 16 6 17.472 $<0.001^*$ Note: * indicates statistically 8 2 9.466 0.002		e	16/13	31/20	0.240	0.624
Note: * indicates statisticallyplatelet Count 200.41 ± 53.41 197.67 ± 56.16 0.214 0.831 GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ volume 16 6 17.472 $<0.001^*$ Note: * indicates statistically 8 2 9.466 0.002		fibrinogen level	1.67 ± 0.68	2.33 ± 0.60	4.517	< 0.001*
GCS score at admission 6.79 ± 1.93 11.78 ± 2.55 9.147 $<0.001^*$ Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ pulmonary infection 16 6 17.472 $<0.001^*$ Note: * indicates statisticallystress ulcer 8 2 9.466 0.002		blood lactate level	2.52 ± 0.36	1.74 ± 0.42	8.348	< 0.001*
Length of stay 29.93 ± 8.64 16.65 ± 9.00 6.443 $<0.001^*$ pulmonary infection 16 6 17.472 $<0.001^*$ Note: * indicates statistically stress ulcer 8 2 9.466 0.002		platelet Count	200.41 ± 53.41	197.67 ± 56.16	0.214	0.831
pulmonary infection16617.472<0.001*Note: * indicates statisticallystress ulcer829.4660.002		GCS score at admission	6.79 ± 1.93	11.78 ± 2.55	9.147	< 0.001*
Note: * indicates statistically stress ulcer 8 2 9.466 0.002		Length of stay	29.93 ± 8.64	16.65 ± 9.00	6.443	< 0.001*
Note: * indicates statistically		pulmonary infection	16	6	17.472	< 0.001*
	Note: * indicates statistically	stress ulcer	8	2	9.466	0.002
		GOS score	2.66 ± 0.55	4.53 ± 0.50	15.437	< 0.001*

Comparison of the clinical data between the fibrinogen decreased group and fibrinogen normal group

Among the 80 patients, 34 had decreased fibrinogen levels. There were no significant differences between the fibrinogen-decreased group and the fibrinogen-normal group in terms of age, sex ratio, and platelet count (P > 0.05, Table 2). However, the fibrinogen-decreased group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, lower GOS scores, and a higher proportion of patients with GOS <4 (P < 0.05, Table 2).

Comparison of the clinical data between the poor prognosis group and good prognosis group

Among the 80 patients, 29 had a poor prognosis (GOS score < 4). There were no significant differences between the poor prognosis group and the good prognosis group in terms of age, sex ratio, and platelet count (P > 0.05, Table 3). However, the poor prognosis group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, a higher proportion of patients with pulmonary infections, a higher incidence of stress ulcers, and lower GOS scores (P < 0.05, Table 3).

Discussion

In recent years, there has been a significant improvement in the understanding of the pathology of TBI. Additionally, TBI is a leading cause of disability and death in children. The series of injuries that occur following pediatric TBI, including scalp injuries, skull fractures, and brain tissue damage, are similar to those seen in adults. However, due to the immaturity of various organ systems in children, if effective treatment is not provided following TBI, it may have lifelong detrimental effects in children. Statistics have shown that over 470,000 children aged 0–4 years suffered from TBI, with more than 30,000 requiring hospitalization and over 2,000 deaths resulting from TBI, in the United States [7, 8].

Blood lactate, a product of anaerobic glycolysis in the body, is normally processed by the liver to maintain stable levels. When lactate production exceeds the liver's processing capacity, lactate accumulation occurs in the body. Therefore, the level of lactate in the body can reflect glucose metabolism, tissue perfusion, and other conditions. There is evidence that lactate levels can reflect the severity and prognosis of neurological diseases such as aneurysmal subarachnoid hemorrhage [9].

Our study divided the patients into an elevated blood lactate group and a normal blood lactate group. We found that the patients in the elevated blood lactate group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, lower GOS scores, and a higher proportion of patients with GOS < 4. The same results were also confirmed in Wang's study [10]. A study conducted at the Nanjing General Hospital of Nanjing Military Command showed that blood lactate levels were correlated with heart rate and systolic blood pressure, which are classical prognostic indicators for shock patients. The study also found that arterial blood lactate levels in patients who died from traumatic brain injury were significantly higher than those in nondeath patients.

Moreover, in our findings, the patients were classified into good prognosis and poor prognosis groups, and we found that the blood lactate levels in the good prognosis group were significantly lower than those in the poor prognosis group (P < 0.001). The same results were also confirmed in Svedung's study [11]. In a case analysis conducted at the Neurosurgery Department of Qinghai Provincial People's Hospital, strict control of each step was implemented, and for the first time, the volume of cerebral contusion and the average CT value in the edema area were included in the model. It was found that the ratio of glucose to lactate in cerebrospinal fluid was an independent risk factor for poor prognosis in cerebral contusion [12]. A study [13] has shown that in patients with spontaneous intracerebral hemorrhage, fibrinogen levels are an independent predictor of hematoma expansion. In our study, based on whether fibrinogen levels were decreased, we found that the patients in the decreased fibrinogen group had lower GCS scores upon admission, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, lower GOS scores, and a higher proportion of patients with GOS < 4 (P < 0.05). In Zhang's study [14], plasma fibrinogen levels were found to be an independent factor influencing intracranial hematoma volume in patients with acute traumatic brain injury (r =-3.40, P < 0.001). Moreover, the group of patients with poor prognosis exhibited lower GCS scores, higher blood lactate levels, lower fibrinogen levels, longer hospital stays, a higher incidence of pulmonary infection, a higher incidence of stress ulcers, and lower GOS scores. The GCS score upon admission is one of the rapid assessment tools for evaluating the condition of patients with traumatic brain injury, and a lower score indicates a more severe condition. On the other hand, blood lactate levels upon admission reflect both the metabolic perfusion status and serve as biomarkers for the body's stress response. When the body is under stress, stress-induced hyperglycemia may occur [15]. Existing evidence suggests that in patients with moderate to severe traumatic brain injury, those who did not survive had higher blood lactate levels upon admission, indicating a correlation between elevated lactate levels, high blood glucose levels, abnormal coagulation function, and the severity of brain injury [16]. However, further research is needed to investigate the relationship between elevated blood lactate levels and stress-induced hyperglycemia in children with traumatic brain injury. Fibrinogen, coagulation factor I, participates in the process of thrombus formation through interactions with platelets and other coagulation factors. Animal model studies have shown that the consumption of fibrinogen can mitigate the progression and severity of certain diseases and may serve as a potential therapeutic approach [17]. In our study, 34 of the 80 patients showed decreased fibrinogen levels, which may indicate a poor prognosis in children with traumatic brain injury, consistent with the findings in Lv's study [18]. Additionally, some researchers have studied the ratio of D-dimer to fibrinogen upon admission as a predictive factor for the progression of intracranial hematoma. A study from Japan confirmed that supplementing fresh frozen plasma to raise fibrinogen levels can improve the prognosis of patients with traumatic brain injury [19]. Some studies have indicated that elevated fibrinogen levels increase the risk of other complications, such as thrombosis [20, 21].

Honestly, most of the results are derived from retrospective studies, but there is a lack of evidence from large-scale, multicenter prospective studies. Therefore, for pediatric traumatic brain injury, the optimal fibrinogen level for improving prognosis still requires further analysis using large-scale data. Additionally, in our data analysis, we found that patients with elevated blood lactate levels had lower fibrinogen levels. Whether there is a correlation between elevated blood lactate levels, representative of coagulation function, and fibrinogen levels in pediatric traumatic brain injury needs to be further confirmed.

Acknowledgements Not applicable.

Author contributions Chang-pin Liao conceived and designed the experiments. Peng Yan, Cheng-jian Qin, Hao He analyzed the data, Kunyuan Zhang, Pei-long Li wrote the main manuscript text, Kun-yuan Zhang prepared figures. All authors reviewed the manuscript.

Data availability All the data obtained and materials analyzed in this research are available with the corresponding author upon reasonable request.

Declarations

Ethics approval Not applicable.

Consent for publication All authors have read and agreed to the published version of the manuscript.

Conflict of interest All authors declare that they have no conflict of interest.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- ARAKI T, YOKOTA, H., MORITA A (2017) Pediatric Traumatic Brain Injury: characteristic features, diagnosis, and management. Neurologia medico-chirurgica 57(2):82–93. https://doi. org/10.2176/nmc.ra.2016-0191
- Carteron L, Solari D, Patet C, Quintard H, Miroz JP, Bloch J, Oddo M (2018) Crit Care Med 46(10):1649–1655 [Journal Article; Research Support, Non-U.S. Gov't]. https://doi.org/10.1097/ CCM.000000000003274. Hypertonic Lactate to Improve Cerebral Perfusion and Glucose Availability After Acute Brain Injury
- Chen C, Chen CPC, Chen C, Hsieh Y, Chung C, Liao C (2021) Predictors of In-Hospital mortality for school-aged children with severe traumatic brain Injury. Brain Sci 11(2):136. https://doi. org/10.3390/brainsci11020136

- Dewan MC, Mummareddy N, Wellons JR, Bonfield CM (2016) Epidemiology of global Pediatric Traumatic Brain Injury: qualitative review. Review] World Neurosurg 91:497–509. [Journal Article10.1016/j.wneu.2016.03.045
- Fu YQ, You CY, Liu CJ, Xu F (2020) [Interpretation of guideline for the management of pediatric severe traumatic brain injury (third edition)]. [Journal Article]. Zhonghua Er Ke Za Zhi 58(1):9– 12. https://doi.org/10.3760/cma.j.issn.0578-1310.2020.01.004
- Fu Y, Bai K, Liu C (2019) The impact of admission serum lactate on children with moderate to severe traumatic brain injury. PLoS ONE 14(9):e222591. https://doi.org/10.1371/journal. pone.0222591
- Jiang W, Fu J, Chen F, Zhan Q, Wang Y, Wei M, Xiao B (2020) Basal ganglia infarction after mild Head Trauma in pediatric patients with basal ganglia calcification. [Journal Article]. Clin Neurol Neurosurg 192:105706. https://doi.org/10.1016/j. clineuro.2020.105706
- Lee JH (2023) The association between lactate to albumin ratio and outcomes at early phase in patients with traumatic brain injury. Turkish J Trauma Emerg Surg. https://doi.org/10.14744/ tjtes.2023.40033
- Liu J, Xu H, Chen Q, Zhang T, Sheng W, Huang Q, Yang Y (2019) Prediction of hematoma expansion in spontaneous intracerebral Hemorrhage using support vector machine. EBioMedicine 43:454–459. https://doi.org/10.1016/j.ebiom.2019.04.040
- Lozano A, Franchi F, Seastres RJ, Oddo M, Lheureux O, Badenes R, Taccone FS (2020) Glucose and lactate concentrations in Cerebrospinal Fluid after Traumatic Brain Injury. [Journal Article]. J Neurosurg Anesthesiol 32(2):162–169. https://doi.org/10.1097/ ANA.000000000000582
- Lv K, Yuan Q, Fu P, Wu G, Wu X, Du Z, Hu J (2020) Impact of fibrinogen level on the prognosis of patients with traumatic brain injury: a single-center analysis of 2570 patients. World J Emerg Surg 15(1). https://doi.org/10.1186/s13017-020-00332-1
- Nakae R, Fujiki Y, Takayama Y, Kanaya T, Igarashi Y, Suzuki G, Yokobori S (2020) Age-related differences in the Time Course of Coagulation and fibrinolytic parameters in patients with traumatic brain Injury. Int J Mol Sci 21(16):5613. https://doi.org/10.3390/ ijms21165613
- NAKAE R, MURAI Y, TAKAYAMA Y, NAMATAME K, MAT-SUMOTO Y, KANAYA T, YOKOBORI S (2022) Neurointensive Care of Traumatic Brain Injury patients based on coagulation and fibrinolytic parameter monitoring. Neurologia medico-chirurgica 62(12):535–541. https://doi.org/10.2176/jns-nmc.2022-0226
- Nakae R, Yokobori S, Takayama Y, Kanaya T, Fujiki Y, Igarashi Y, Yokota H (2019) A retrospective study of the effect of fibrinogen levels during fresh frozen plasma transfusion in patients with traumatic brain injury. Acta Neurochir (Wien) 161(9):1943–1953. https://doi.org/10.1007/s00701-019-04010-3. [Journal Article; Research Support, Non-U.S. Gov't]
- Sulimai N, Lominadze D (2020) Fibrinogen and Neuroinflammation during Traumatic Brain Injury. Mol Neurobiol 57(11):4692– 4703. https://doi.org/10.1007/s12035-020-02012-2
- Svedung Wettervik T, Lewén A, Enblad P (2023) Fine tuning of neurointensive care in aneurysmal subarachnoid Hemorrhage: from one-size-fits-all towards individualized care. World Neurosurgery: X 18:100160. https://doi.org/10.1016/j. wnsx.2023.100160
- Svedung WT, Engquist H, Howells T, Rostami E, Hillered L, Enblad P, Lewén A (2020) Arterial lactate in traumatic brain injury - relation to intracranial pressure dynamics, cerebral energy metabolism and clinical outcome. J Crit Care 60:218–225. https:// doi.org/10.1016/j.jcrc.2020.08.014. [Journal Article; Research Support, Non-U.S. Gov't]
- Tsai Y, Wu S, Hsieh T, Liu H, Huang C, Chou S, Hsieh C (2020) Association of stress-Induced Hyperglycemia and Diabetic

Hyperglycemia with Mortality in patients with traumatic Brain Injury: analysis of a Propensity score-matched Population. Int J Environ Res Public Health 17(12):4266. https://doi.org/10.3390/ ijerph17124266

- Wang Y, Zhu N, Zhou Y, Su R, Li H, Zhou J (2022) The combination of arterial lactate level with GCS-pupils score to evaluate short term prognosis in traumatic brain injury: a retrospective study. BMC Neurol 22(1). https://doi.org/10.1186/s12883-022-02970-1
- 20. You C, Lu S, Fu Y, Xu F (2021) Relationship between admission coagulopathy and prognosis in children with traumatic brain

injury: a retrospective study. Scand J Trauma Resusc Emerg Med 29(1). https://doi.org/10.1186/s13049-021-00884-4

 Zhu Y, Jin X, Xu L, Han P, Lin S, Lu Z (2021) Establishment and validation of prognosis model for patients with cerebral contusion. BMC Neurol 21(1). https://doi.org/10.1186/s12883-021-02482-4

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.